We then found that after MLN4924 treatment, SLC7A11 levels were remarkably increased in time- and dose-dependent manners in multiple lines of cancer cells, while the SLC3A2 levels were increased moderately in a cell line–dependent manner (Fig. 1 B and C and SI Appendix, Fig. S1 A–C). This evidence concerns the gene SLC3A2 and cancer.